Market Research Logo

Lassa Fever - Pipeline Review, H1 2016

Lassa Fever - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Lassa Fever - Pipeline Review, H1 2016’, provides an overview of the Lassa Fever pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Lassa Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lassa Fever and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Lassa Fever
  • The report reviews pipeline therapeutics for Lassa Fever by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Lassa Fever therapeutics and enlists all their major and minor projects
  • The report assesses Lassa Fever therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Lassa Fever
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Lassa Fever
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Lassa Fever pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Lassa Fever Overview
Therapeutics Development
Pipeline Products for Lassa Fever - Overview
Pipeline Products for Lassa Fever - Comparative Analysis
Lassa Fever - Therapeutics under Development by Companies
Lassa Fever - Therapeutics under Investigation by Universities/Institutes
Lassa Fever - Pipeline Products Glance
Early Stage Products
Lassa Fever - Products under Development by Companies
Lassa Fever - Products under Investigation by Universities/Institutes
Lassa Fever - Companies Involved in Therapeutics Development
Arno Therapeutics, Inc.
Celgene Corporation
Etubics Corporation
Kineta, Inc.
Profectus BioSciences, Inc.
SIGA Technologies, Inc.
Lassa Fever - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AR-12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CC-11050 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DEF-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FBH-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FDX-000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KIN-1400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lassa fever vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lassa fever vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lassa fever vaccine 1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lassa fever vaccine 2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LHF-535 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies for Lassa Fever - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies for Viral Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit NPC1 for Ebola and Lassa Fever Virus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-193 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Lassa Fever - Dormant Projects
Lassa Fever - Product Development Milestones
Featured News & Press Releases
May 05, 2016: Kineta Receives Wellcome Trust Award to Advance Novel Therapeutic for Lassa Fever into Clinical Trials
Apr 22, 2016: Kineta Presents Promising New Data on Novel Lassa Fever Antiviral and Broad Spectrum Innate Immune Antivirals
May 28, 2015: Arno Therapeutics Announces AR-12 Antiviral Data Against Multiple Hemorrhagic Fevers Published Online in Antiviral Research
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Lassa Fever, H1 2016
Number of Products under Development for Lassa Fever - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Early Stage Development, H1 2016
Products under Development by Companies, H1 2016
Products under Investigation by Universities/Institutes, H1 2016
Lassa Fever - Pipeline by Arno Therapeutics, Inc., H1 2016
Lassa Fever - Pipeline by Celgene Corporation, H1 2016
Lassa Fever - Pipeline by Etubics Corporation, H1 2016
Lassa Fever - Pipeline by Kineta, Inc., H1 2016
Lassa Fever - Pipeline by Profectus BioSciences, Inc., H1 2016
Lassa Fever - Pipeline by SIGA Technologies, Inc., H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Lassa Fever - Dormant Projects, H1 2016
List of Figures
Number of Products under Development for Lassa Fever, H1 2016
Number of Products under Development for Lassa Fever - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Targets, H1 2016
Number of Products by Stage and Targets, H1 2016
Number of Products by Mechanism of Actions, H1 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Types, H1 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report